tirzepatide vs semaglutide weight loss comparison study Cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice Tirzepatide vs Semaglutide: Key Weight

[12] GH secretion may exacerbate insulin resistance, so patients may require frequent glucose monitoring, especially those with diabetes or prediabetes

Participants also showed improvements in cardiovascular risk factors and metabolic markers

Detailed instructions for use are on the other side of this leaflet

Participants must be adults aged 1875 with moderately to severely active UC confirmed by endoscopy and histology, having at least 15 cm disease extent from anal verge, modified MS of 59 points with MES of at least 2, and inadequate response or intolerance to prior treatments including corticosteroids, immunomodulators, or advanced therapies, while excluding those with CD, toxic megacolon, prior vedolizumab exposure, or contraindicated medications, with the study completing primary outcomes in October 2025 and final completion estimated for February 2027

Hopeful second month will have good results also